Fleury (FLRY3) Q2 2026 earnings summary

Executive summary

• Achieved significant revenue growth, margin expansion, and net income increase in Q2 2026, driven by organic growth and strategic acquisitions, especially in B2C Diagnostic Medicine.

• B2C diagnostic medicine remains the largest revenue contributor, with strong performance across all regions and brands.

• Maintained stable leverage and improved ROIC, reflecting disciplined capital allocation.

• Completed acquisition of Femme in Q2 2026, expanding the portfolio in women's health.

• Continued focus on operational efficiency, digital innovation, and nationwide integration.

Financial highlights

• Gross revenue grew 14.4% year-over-year to R$2.5 billion in Q2 2026; organic growth was 12.1%.

• EBITDA rose 15.2% to R$612.9 million, with a margin of 26.5%.

• Net income increased 45.7% to R$221.9 million, with net margin at 9.6%.

• Gross profit grew 22% to R$644.1 million, margin of 27.8%.

• Operating cash flow reached R$695.8 million, up 42.9% year-over-year, with 100.5% EBITDA cash conversion.

Outlook and guidance

• Confident in continued strong performance for the second half of 2026, with no major calendar effects expected.

• Ongoing expansion of Lab-to-Lab and Novos Elos expected to drive further growth.

• Integration of recent acquisitions, including Femme, to strengthen B2C presence.

• Tax rate expected to remain around 21-22% for the year, with minor adjustments possible.

• Emphasis on integration of patient journey and nationwide reach through diversified business units.